Jia Jie Biomedical Co (ROCO:4109) Piotroski F-Score: 4 (As of Jul. 03, 2026) — 20% Below Median


ROCO:4109 Jia Jie Biomedical Co Ltd ROCO:4109
60 GF Score
Price NT$12.80
GF Value NT$16.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Jia Jie Biomedical Co Piotroski F-Score?

Jia Jie Biomedical Co ROCO:4109 +9.87% 60 Piotroski F-Score is 4 as of Jul. 03, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates ROCO:4109 with a GF Score™ of 60/100 and a GF Value™ of NT$16.91 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,909 Consumer Packaged Goods companies, Jia Jie Biomedical Co ranks worse than 66.95% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jia Jie Biomedical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Jia Jie Biomedical Co's Piotroski F-Score or its related term are showing as below:

ROCO:4109' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of Jia Jie Biomedical Co was 5. The lowest was 2. And the median was 5.

Jia Jie Biomedical Co  (ROCO:4109) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jia Jie Biomedical Co Piotroski F-Score Related Terms


Jia Jie Biomedical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Jia Jie Biomedical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jia Jie Biomedical Co Piotroski F-Score Chart

Jia Jie Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 4.00 5.00 4.00

Jia Jie Biomedical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 6.00 4.00

ROCO:4109 vs KHC, GIS: Piotroski F-Score Comparison

For the Packaged Foods subindustry, Jia Jie Biomedical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jia Jie Biomedical Co Piotroski F-Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Jia Jie Biomedical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jia Jie Biomedical Co's Piotroski F-Score falls into.


ROCO:4109
60GF Score
Jia Jie Biomedical Co Ltd ROCO:4109
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 13.459 + -0.691 + 10.162 + 27.33 = NT$50.3 Mil.
Cash Flow from Operations was 12.934 + -3.194 + 0.281 + 11.322 = NT$21.3 Mil.
Revenue was 132.864 + 106.004 + 112.706 + 133.829 = NT$485.4 Mil.
Gross Profit was 47.843 + 37.988 + 31.444 + 33.061 = NT$150.3 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(1482.284 + 1874.708 + 1832.298 + 1839.534 + 1888.888) / 5 = NT$1783.5424 Mil.
Total Assets at the begining of this year (Dec24) was NT$1,482.3 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.2 Mil.
Total Current Assets was NT$574.5 Mil.
Total Current Liabilities was NT$170.8 Mil.
Net Income was 13.31 + 214.694 + 3.043 + -19.675 = NT$211.4 Mil.

Revenue was 160.011 + 151.203 + 95.397 + 130.459 = NT$537.1 Mil.
Gross Profit was 50.991 + 48.75 + 30.916 + 42.691 = NT$173.3 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(1412.913 + 1371.63 + 1579.672 + 1497.075 + 1482.284) / 5 = NT$1468.7148 Mil.
Total Assets at the begining of last year (Dec23) was NT$1,412.9 Mil.
Long-Term Debt & Capital Lease Obligation was NT$2.0 Mil.
Total Current Assets was NT$348.3 Mil.
Total Current Liabilities was NT$116.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jia Jie Biomedical Co's current Net Income (TTM) was 50.3. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jia Jie Biomedical Co's current Cash Flow from Operations (TTM) was 21.3. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=50.26/1482.284
=0.03390713

ROA (Last Year)=Net Income/Total Assets (Dec23)
=211.372/1412.913
=0.14960015

Jia Jie Biomedical Co's return on assets of this year was 0.03390713. Jia Jie Biomedical Co's return on assets of last year was 0.14960015. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jia Jie Biomedical Co's current Net Income (TTM) was 50.3. Jia Jie Biomedical Co's current Cash Flow from Operations (TTM) was 21.3. ==> 21.3 <= 50.3 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=0.236/1783.5424
=0.00013232

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1.993/1468.7148
=0.00135697

Jia Jie Biomedical Co's gearing of this year was 0.00013232. Jia Jie Biomedical Co's gearing of last year was 0.00135697. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=574.476/170.835
=3.36275353

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=348.336/116.849
=2.98107814

Jia Jie Biomedical Co's current ratio of this year was 3.36275353. Jia Jie Biomedical Co's current ratio of last year was 2.98107814. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jia Jie Biomedical Co's number of shares in issue this year was 118.817. Jia Jie Biomedical Co's number of shares in issue last year was 98.744. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=150.336/485.403
=0.30971378

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=173.348/537.07
=0.32276612

Jia Jie Biomedical Co's gross margin of this year was 0.30971378. Jia Jie Biomedical Co's gross margin of last year was 0.32276612. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=485.403/1482.284
=0.32746963

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=537.07/1412.913
=0.38011541

Jia Jie Biomedical Co's asset turnover of this year was 0.32746963. Jia Jie Biomedical Co's asset turnover of last year was 0.38011541. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jia Jie Biomedical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Jia Jie Biomedical Co (ROCO:4109) has a Piotroski F-Score of 4 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jia Jie Biomedical Co and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Jia Jie Biomedical Co's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Jia Jie Biomedical Co ranks #1278 out of 1909 companies in the Consumer Packaged Goods industry, placing it in the top 66.9%.
Is Jia Jie Biomedical Co's Piotroski F-Score too high?
Jia Jie Biomedical Co's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. Jia Jie Biomedical Co's value of 4 is 20% below this industry median. Based on the distribution chart, Jia Jie Biomedical Co ranks #1278 out of 1909 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Jia Jie Biomedical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jia Jie Biomedical Co's Piotroski F-Score compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Jia Jie Biomedical Co ranks #1278 out of 1909 companies for Piotroski F-Score. This places Jia Jie Biomedical Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Jia Jie Biomedical Co's value of 4 is 20% below this benchmark. Historically, Jia Jie Biomedical Co's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Jia Jie Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,909 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jia Jie Biomedical Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jia Jie Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jia Jie Biomedical Co's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jia Jie Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Jia Jie Biomedical Co (ROCO:4109) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$16.91, compared to a current price of NT$12.80 — trading 24.3% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Consumer Packaged Goods industry median of 5.00. Jia Jie Biomedical Co's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jia Jie Biomedical Co (ROCO:4109), the current Piotroski F-Score is 4 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jia Jie Biomedical Co (ROCO:4109) Overvalued in 2026?

Based on GuruFocus' analysis, Jia Jie Biomedical Co stock appears to be undervalued. The current stock price of NT$12.80 is trading 24.3% below its estimated GF Value™ of NT$16.91. GuruFocus considers Jia Jie Biomedical Co to be Modestly Undervalued.

Key valuation signals for ROCO:4109:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: NT$16.91 vs. price of NT$12.80 (24.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs
  • Industry Position: 20% below the Consumer Packaged Goods median (#1278 of 1909)

No single metric tells the full story. See the ROCO:4109 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jia Jie Biomedical Co Business Description

Address Jiuru 1st Road, 3rd Floor, No. 61, Sanmin District, Kaohsiung City, TWN, 807
Jia Jie Biomedical Co Ltd is a Taiwan-based company. The Company is engaged in the processing, sale, and trading of softshell turtle food, the Manufacture of Dairy Products, and miscellaneous food manufacturing (e.g., softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules). The company is also engaged in the import, export of the aforementioned products, the distribution, bidding, and quotation of aforementioned products for domestic and foreign manufacturers, Wholesale of Nonalcoholic Beverages, candy wholesale, baked food wholesale, supplementary food wholesale, cosmetics wholesale, and sports equipment wholesale.
60GF Score

Get the complete analysis for ROCO:4109

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.80
Price
NT$16.91
GF Value